BOSTON, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that President and Chief Medical Officer, Evan Loh, MD, will participate in two upcoming investor conferences. Paratek is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry.
Dr. Loh will present at the following events:
- RBC Capital 2016 Global Healthcare Conference on Wednesday, February 24 from 11:30 to 11:55 a.m. at the New York Palace Hotel. To access the live webcast of Paratek's RBC Capital presentation, please visit http://www.veracast.com/webcasts/rbc/healthcare2016/91208404095.cfm. Please connect to the web site at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast can be accessed until May 23, 2016.
- Cowen and Company’s 36th Annual Health Care Conference on Monday, March 7 from 1:20 to 1:50 p.m. at the Boston Marriott Copley Place. To access the live webcast of Paratek's Cowen and Company presentation, please visit http://wsw.com/webcast/cowen30/prtk. Please connect to the web site at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast can be accessed for up to 90 days following the live presentation.
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethylcyclines, with broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria. Paratek initiated a Phase 3 registration study in ABSSSI in June 2015 to determine the efficacy and safety of omadacycline compared to linezolid. Top-line data from this study will be available in mid-2016. A Phase 3 registration study for CABP with omadacycline was initiated in November 2015.
Omadacycline is a new once-daily oral and IV, well-tolerated broad-spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial infections, such as acute bacterial skin and skin structure infections, community acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians.
Paratek's second Phase 3 product candidate, sarecycline, is a new once-daily oral tetracycline-derived compound for the potential treatment of acne and rosacea in the community setting. Sarecycline is designed to be a well-tolerated, once-daily, oral, narrow spectrum antibiotic with anti-inflammatory properties. Allergan owns the U.S. rights for the development and commercialization of sarecycline.
Paratek retains all ex-U.S. rights. Two identical Phase 3 registration studies were initiated by Allergan in December 2014 for sarecycline for the treatment of moderate to severe acne vulgaris.
For more information, visit www.paratekpharma.com.
CONTACTS: Media Relations: Michael Lampe (484) 575-5040 firstname.lastname@example.org Investor Relations: Hans Vitzthum LifeSci Advisors, LLC. 212-915-2568